Business description
Werewolf Therapeutics is a highly innovative company striving to redefine the cancer treatment landscape with potential best-in-class therapies. It develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. They invented proprietary PREDATOR™ protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients.
Management board & Supervisory board
CEO |
Dan Hicklin |
Management board |
Tim Trost, Randi Isaacs, Chulani Karunatilake, Ellen Lubman, Cynthia Seidel-Dugan |
Supervisory board |
Luke Evnin, Michael Atkins, Meeta Chatterjee, Derek DiRocco, Dan Hicklin, Alon Lazarus, Briggs W. Morrison, Mike Sherman |
Company data
Name: |
Werewolf Therapeutics Inc |
Address: |
200 Talcott Avenue, 2nd Floor,Watertown, MA 02472 |
Phone: |
+1 617-952-0555 |
Fax: |
- |
E-mail: |
info@werewolftx.com
|
Internet: |
https://werewolftx.com/ |
Industry: |
Biotechnology |
Sector: |
Biotechnology |
Sub sector: |
- |
End of financial year: |
12/31 |
Free Float: |
- |
IPO date: |
4/29/2021 |
Investor relations
Name: |
Josh Rappaport |
IR phone: |
+1 212-362-1200 |
IR Fax: |
- |
IR e-mail: |
IR@werewolftx.com
|